Overview

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness of fexinidazole administered to patients with g-HAT at all stages of the disease. The aim of the present study is to provide additional information on the effectiveness and safety of fexinidazole and to assess its use under conditions as close as possible to those in real life, both in patients treated on an out-patient basis and in the hospital setting, depending on clinical status
Phase:
Phase 3
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborator:
Sanofi